Results 91 to 100 of about 5,561,146 (281)

Cumhuriyet İlahiyat Dergisi Yeni Sayı: Cilt 24 Sayı 2

Cumhuriyet İlahiyat Dergisi, 2020
Değerli okuyucularımız, Cumhuriyet İlahiyat Dergisi’nin 24. Cilt 2. Sayısına hoşgeldiniz. Bu sayımızla birlikte 25. yaşımıza girecek olmanın heyecanını ve mutluluğunu yaşıyoruz.
Sema Yılmaz
doaj  

Letter From the Chief Editor [PDF]

, 2018
Verenize Arceo
openalex   +1 more source

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis

Molecular Oncology, Volume 19, Issue 12, Page 3651-3664, December 2025.
This study highlights the potential of automated enumeration using the ACCEPT software to refine circulating tumor cell (CTC) detection in metastatic colorectal cancer (mCRC). The automated method demonstrates improved accuracy and reduced variability compared to the manual approach.
Michela De Meo, Marco Siringo, Alessandro Vici, Ann Zeuner, Orietta Gandini, Paola Gazzaniga, Chiara Nicolazzo   +6 more
wiley   +1 more source

Cumhuriyet İlahiyat Dergisi Yeni Sayı: Cilt 24 Sayı 3

Cumhuriyet İlahiyat Dergisi, 2020
Değerli okurlarımız, Cumhuriyet İlahiyat Dergisi’nin 24. Cilt 3. Sayısı Temel İslam Bilimleri Özel Sayısına hoş geldiniz. Bu sayımızda da birçok güncel araştırmayı sizlere sunmaktan heyecan ve mutluluk duyuyoruz.
Sema Yılmaz
doaj  

Dispatches from the editor: blast injury is everyone’s problem [PDF]

, 2018
Jeff Garner, John Breeze
openalex   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

From the Editor [PDF]

, 1996
Smith, Pete
core   +5 more sources

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

From the Editors [PDF]

, 2008
T. Gansler, O. W. Brawley
openalex   +3 more sources